The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02730416
Recruitment Status : Completed
First Posted : April 6, 2016
Last Update Posted : September 21, 2023
Sponsor:
Collaborators:
North Eastern German Society of Gynaecological Oncology
Belgian Gynaecological Oncology Group
ARCAGY/ GINECO GROUP
Information provided by (Responsible Party):
Nordic Society of Gynaecological Oncology - Clinical Trials Unit

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study will evaluate the role of addition of an anti-angiogenic agent (Nintedanib/placebo) to conventional combination chemotherapy as concomitant and maintenance treatment in primary advanced or with first relapse of endometrial cancer.

Condition or disease Intervention/treatment Phase
Endometrial Cancer Drug: Nintedanib or Placebo; Carboplatin, Paclitaxel Phase 2

Detailed Description:

This multicenter, prospective, double-blind, placebo-controlled, randomised phase 2 study is evaluating combination chemotherapy with nintedanib in patients with primary advanced stage (3C2 & 4), or with first relapse of endometrial cancer.

Patients are stratified according to:

  1. Stage of disease (stage 3C2 vs. stage 4 vs. recurrent disease)
  2. Prior adjuvant chemotherapy (yes/no)
  3. Disease status (Measurable disease vs. non-measurable /RECIST 1.1)

Patients are randomized to one of the two treatment arms 1:1 randomization:

  • Arm A: Paclitaxel and Carboplatin (6 courses) and Nintedanib (until PD). (Experimental arm)
  • Arm B: Paclitaxel and Carboplatin (6 courses) and Placebo (until PD) (Control Arm)

Primary endpoint is PFS. 148 patients to be enrolled.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 146 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: ENGOT-EN1/FANDANGO: A Randomized Phase II Trial of First-line Combination Chemotherapy With Nintedanib / Placebo for Patients With Advanced or Recurrent Endometrial Cancer
Actual Study Start Date : December 12, 2016
Actual Primary Completion Date : October 20, 2021
Actual Study Completion Date : November 25, 2021

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: A: Nintedanib
Nintedanib 200mg twice daily days 2-21 every 21 days for 6 courses during simultaneous treatment with carboplatin-paclitaxel; afterwards in maintenance 200mg twice daily days 1-21 every 21 days. Treatment continues until progression or unacceptable toxicity.
 Drug: Nintedanib or Placebo; Carboplatin, Paclitaxel
Arm A: Nintedanib: 200mg orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD Arm B: Placebo: orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD In both arms: 6 courses of standard carboplatin and paclitaxel: Carboplatin AUC 5 iv every 21 days; Paclitaxel 175mg/m2 iv every 21 days. Both drugs are continued for maximum six courses or until unacceptable toxicity
Placebo Comparator: B: Placebo
Placebo twice daily days 2-21 every 21 days for 6 courses during simultaneous treatment with carboplatib-paclitaxel; afterwards in maintenance 200mg twice daily days 1-21 every 21 days. Treatment continues until progression or unacceptable toxicity.
 Drug: Nintedanib or Placebo; Carboplatin, Paclitaxel
Arm A: Nintedanib: 200mg orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD Arm B: Placebo: orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD In both arms: 6 courses of standard carboplatin and paclitaxel: Carboplatin AUC 5 iv every 21 days; Paclitaxel 175mg/m2 iv every 21 days. Both drugs are continued for maximum six courses or until unacceptable toxicity


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. PFS: Difference in months of Median Progression-Free Survival in experimental arm versus comparator arm [ Time Frame: 36 months ]
    Superiority of Nintedanib arm vs. placebo arm by median PFS increase of 4 months (from 10 months to 14 months) HR: 1.4; power80%; one-sided alpha: 15%. Inclusion period 18 months. Median PFS matures after 14 months of end inclusion


Secondary Outcome Measures :
  1. PFS in the sub-populations as described under stratification factors [ Time Frame: 32 months ]
    To be measured (in months) and reported

  2. PFS after consecutive treatment (PFS2). To be measured (in months) and reported [ Time Frame: 48 months ]
    PFS2 is defined along the same timelines as PFS but accounts for the time from randomization to progression or death by any cause on any subsequent line of anticancer therapy.

  3. Disease Specific Survival (DSS) [ Time Frame: 48 months ]
    To be measured (in months) and reported

  4. TSST (Time to Second Subsequent Therapy) [ Time Frame: 48 months ]
    To be measured (in months) and reported

  5. TFST (Time to First Subsequent Therapy) [ Time Frame: 48 months ]
    To be measured (in months) and reported

  6. Overall Survival (OS) [ Time Frame: 48 months ]
    To be measured (in months) and reported

  7. Response Rate (RR). [ Time Frame: 32 months ]
    To be measured (CRs & PRs in %) and reported

  8. Disease Control Rate (DCR) [ Time Frame: 32 months ]
    Disease Control Rate (DCR = Complete Response, Partial Response or Stable Disease for at least 12 weeks). To be measured (CRs, PRs & SDs in %) and reported

  9. Patient Related Outcomes (PROs) [ Time Frame: 48 months ]
    Patient questionnaire results to be presented as as narrative (1-10 scale)

  10. Number of patients with Grade 3 through Grade 5 Adverse Events that are related to study drug. [ Time Frame: 36 months ]
    NCI CTCAE Version 4.0

  11. Compliance in the two treatment arms [ Time Frame: 32 months ]
    Percentage of missed dosages during the treatment


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histological confirmed endometrial cancer. (FIGO 2009)

    1. Stage 3C 2
    2. Stage 4 A & B
    3. Relapsed after adjuvant therapy for stage 1-3 disease
  2. Patients may have undergone primary surgery.
  3. Patients may have received adjuvant chemotherapy for stage 1 - 3.
  4. Patients may have received vaginal brachytherapy
  5. Patients may have received external beam radiotherapy. Patients who are to be enrolled for stage 3C2 diseases are allowed to receive external beam radiotherapy prior to trial entry.
  6. Patients may have received hormonal treatment
  7. Patients must have measurable disease or non-measurable disease on CT scan according to RECIST 1.1 outside irradiated field. For stage 3C2 disease patients without measureable or non-measureable disease are accepted.
  8. Patients must give informed consent
  9. ECOG performance status of 0 -1
  10. Patients must have an adequate organ function
  11. Life expectancy of at least 12 weeks
  12. Patients must be fit to receive combination chemotherapy
  13. Patient's age >18 years
  14. Patients with preserved reproductive capacity must have a negative pregnancy test (β-HCG test in urine or serum) prior to commencing study treatment

Exclusion Criteria:

  1. Sarcomas, small cell carcinoma with neuroendocrine differentiation or non-epithelial cancers.
  2. Concurrent cancer therapy
  3. Previous Chemotherapy for stage 4 disease or for relapsed disease.
  4. Previous treatment with anti-angiogenic/anti VEGF therapy including nintedanib.
  5. Concurrent treatment with an investigational agent or participation in another clinical trial.
  6. Treatment within 28 days prior to randomisation with any investigational drug, radiotherapy, immunotherapy, chemotherapy, hormonal therapy or biological therapy. Palliative radiotherapy may be permitted for symptomatic control of pain from bone metastases in extremities, provided that the radiotherapy does not involve target lesions, and the reason for the radiotherapy does not reflect progressive disease.
  7. Major injuries or surgery within the past 21 days prior to start of study treatment with incomplete wound healing and/or planned surgery during the on-treatment study period.
  8. Relapse within six months after adjuvant chemotherapy (treatment-free interval < 182 days).
  9. Previous malignant disease, except patients with other malignant disease, for which the patient has been disease-free for at least three years. Concurrent other malignant disease except for curatively treated carcinoma in situ of the cervix or basal cell carcinoma of the skin.
  10. Active infection or other serious underlying medical condition, which might prevent the patient from receiving treatment or to be followed.
  11. Evidence of significant medical illness, abnormal laboratory finding or psychiatric illness/social situation that would, in the Investigator's judgement, make the patient inappropriate for this study.
  12. Known contraindications to VEGF directed therapy Target Disease Exceptions
  13. Known uncontrolled hypersensitivity to the investigational drugs.

  14. History of major thromboembolic event defined as:

    • Uncontrolled pulmonary embolism (PE)
    • Deep venous thrombosis (DVT)
    • Other related conditions, though patients with stable therapeutic anticoagulation for more than three months prior randomization are eligible for this study.
  15. History of a cerebral vascular accident, transient ischemic attack or subarachnoid haemorrhage within the past 3 months.
  16. History of clinically significant haemorrhage in the past 3 months.
  17. Radiotherapy to the target lesion within the past 3 months prior to baseline imaging
  18. Persistant grade 3 or 4 toxicity from previous chemotherapy and/or radiotherapy, except alopecia. Patients with ongoing ≥ Grade 2 neuropathy are to be excluded.
  19. Active brain metastases (e.g. stable for <4 weeks, no adequate previous treatment with radiotherapy, symptomatic, requiring treatment with anti-convulsants; dexamethasone therapy will be allowed if administered as stable dose for at least one month before randomisation).
  20. Leptomeningeal disease
  21. Significant cardiovascular diseases ( i.e. uncontrolled hypertension, unstable angina, history of infarction within the past 12 months prior to start of study treatment, congestive heart failure > NYHA II, serious cardiac arrhythmia, pericardial effusion) See Appendix 12.
  22. Pregnancy or breastfeeding. Patients with preserved reproductive capacity, unwilling to use a medically acceptable method of contraception for the duration of the trial and for 3 months afterwards.
  23. Radiographic evidence of cavitating or necrotic tumours with invasion of adjacent major blood vessels.
  24. Active or chronic hepatitis C and/or B infection
  25. Known hypersensitivity to the trial drugs, or to their excipients.
  26. Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug
  27. Unable or unwilling to swallow tablets/capsules
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02730416


Locations
Show Show 37 study locations
Sponsors and Collaborators
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
North Eastern German Society of Gynaecological Oncology
Belgian Gynaecological Oncology Group
ARCAGY/ GINECO GROUP
Investigators
Layout table for investigator information
Study Chair: Mansoor R Mirza, MD NSGO
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Nordic Society of Gynaecological Oncology - Clinical Trials Unit
ClinicalTrials.gov Identifier: NCT02730416    
Other Study ID Numbers: ENGOT-EN1/FANDANGO
First Posted: April 6, 2016    Key Record Dates
Last Update Posted: September 21, 2023
Last Verified: September 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Upon request.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Time Frame: From January 2024.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Endometrial Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Diseases
Genital Diseases, Female
Female Urogenital Diseases
Female Urogenital Diseases and Pregnancy Complications
Urogenital Diseases
Genital Diseases
 Paclitaxel
Carboplatin
Nintedanib
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Protein Kinase Inhibitors
Enzyme Inhibitors